Sarcoidal Granulomatous Panniculitis Associated with Immune Checkpoint Inhibitors: A Rare Immune-Mediated Cutaneous Adverse Event
Article Sidebar
Main Article Content
Abstract
Immune checkpoint inhibitors (ICIs), or checkpoint inhibitors, have been associated with various inflammatory and autoimmune adverse effects, known as immune-related adverse events (irAEs). Among irAEs, dermatological toxicities are the most prevalent, with maculopapular rash, pruritus, and lichenoid and psoriasiform eruptions being the most common.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Trilleras-Gómez AP, Hull KJ, Drew DZ. Case report and review of 7 similar cases in the literature: cutaneous sarcoidosis as side effect of pembrolizumab plus chemotherapy in stage IV squamous cell carcinoma of lung. J Immunother. 2021;44(2):90-94. https://doi.org/10.1097/CJI.0000000000000351. DOI: https://doi.org/10.1097/CJI.0000000000000351
Torres-Jiménez J, Esteban-Villarrubia J, García-Abellás P, et al. Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital. Clin Transl Oncol. 2021;23(7):1474-1480. https://doi.org/10.1007/s12094-020-02546-w. DOI: https://doi.org/10.1007/s12094-020-02546-w
Chorti E, Kanaki T, Zimmer L, et al. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. Eur J Cancer. 2020;131:18-26. https://doi.org/10.1016/j.ejca.2020.02.024. DOI: https://doi.org/10.1016/j.ejca.2020.02.024
Juan-Carpena J, Palazón-Cabanes JC, Blanes-Martínez M. Revisión sistemática de los efectos adversos cutáneos causados por fármacos inhibidores de los puntos de control inmunitario: características, manejo y pronóstico. Actas Dermosifiologr. 2022;113(4):376-387. https://doi.org/10.1016/j.ad.2021.09.005. DOI: https://doi.org/10.1016/j.ad.2021.09.005
Suozzi KC, Stahl M, Ko CJ, et al. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep. 2016;2(3):264-268. https://doi.org/10.1016/j.jdcr.2016.05.002. DOI: https://doi.org/10.1016/j.jdcr.2016.05.002
Martínez Leboráns L, Esteve Martínez A, Victoria Martínez AM, et al. Cutaneous sarcoidosis in a melanoma patient under Ipilimumab therapy. Dermatol Ther. 2016;29(5):306-308. https://doi.org/10.1111/dth.12380. DOI: https://doi.org/10.1111/dth.12380
Birnbaum MR, Ma MW, Fleisig S, et al. Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma. JAAD Case Rep. 2017;3(3):208-211. https://doi.org/10.1016/j.jdcr.2017.02.015. DOI: https://doi.org/10.1016/j.jdcr.2017.02.015
Chanson N, Ramos-Casals M, Pundole X, et al. Immune checkpoint inhibitor-associated sarcoidosis: a usually benign disease that does not require immunotherapy discontinuation. Eur J Cancer. 2021;158:208-216. https://doi.org/10.1016/j.ejca.2021.05.041. DOI: https://doi.org/10.1016/j.ejca.2021.05.041
Sibaud V. Dermatologic reactions to immune checkpoint inhibitors : skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19(3):345-361. https://doi.org/10.1007/s40257-017-0336-3. DOI: https://doi.org/10.1007/s40257-017-0336-3
Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119-iv142. https://doi.org/10.1093/annonc/mdx225. Errata en: Ann Oncol. 2018;29(Suppl 4):iv264-iv266. https://doi.org/10.1093/annonc/mdy162. DOI: https://doi.org/10.1093/annonc/mdx225
Abdelghaffar M, Hwang E, Damsky W. Cutaneous sarcoidosis. Clin Chest Med. 2024;45(1):71-89. https://doi.org/10.1016/j.ccm.2023.08.004. DOI: https://doi.org/10.1016/j.ccm.2023.08.004